Healthtech startup Saranas raises $2.8 million in Series C funding to conduct a multi-center clinical pilot

Saranas Inc., a medical device startup with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures. The company’s mission is to provide products that minimize complications associated with medical procedures in the interventional or surgical setting. Our flagship device detects the most common complication associated with over 11 million annual catheterization procedures. The widespread use of this system can significantly improve patient outcomes and lower the cost burden of related complications on patients, hospitals, and insurance providers

Today, the company announced it has completed a $2.8 million Series C funding round. The financing follows the company’s recent De Novo application to the U.S. Food and Drug Administration (FDA) for the Early Bird™ Bleed Monitoring System. The capital will be used to conduct a multi-center clinical pilot in the U.S. and to support the company’s U.S. commercialization plan. Based on publicly available data, the company has raised a total of $18.7 million in funding to date.

We are pleased to bring additional investment and appreciate the confidence shown by so many returning investors. We continue our work to deliver a product to market that has the potential to significantly reduce bleeding complications while reducing related costs to providers and the healthcare system,” said President and CEO Zaffer Syed. “Since our last round of financing, we have completed design verification and validation activities, continued to build our growing intellectual property portfolio, and submitted a De Novo application to the FDA. With this investment, we are well positioned to initiate a multicenter clinical pilot and extend access to this innovative device to patients in the U.S.”

The Early Bird Bleed Monitoring System includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as a transcatheter aortic valve replacement (TAVR), large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.

Founded in 2011 by Mehdi Razavi, Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs.

Razavi, a graduate of University of Michigan and UCLA Anderson School of Business, has over 18 years of medical device industry experience in multiple therapeutic areas including cardiovascular, neuromodulation and dental. He authored over 50 scientific abstract presentations and 10 peer-reviewed journal articles.